• Phalloidin B7678: Practical F-Actin Guide

  2026-09-14

  Phalloidin B7678 is a cyclic heptapeptide toxin used to stabilize and visualize filamentous actin in fixed, permeabilized cells, tissue sections, and cell-free assays. It is intended for endpoint cytoskeleton visualization, not live-cell imaging or experiments requiring reversible actin remodeling.

• Wnt–NR2F2–GPX4 Axis in Brain Metastasis

  2026-09-14

  The reference study identifies a metabolic and transcriptional mechanism underlying acquired platinum resistance in lung cancer-derived brain metastases. Its evidence links glutathione overconsumption, GPX4 and GSTM1 activity, ferroptosis suppression, and Wnt/NR2F2-dependent GPX4 transcription, suggesting a rationale for combining platinum therapy with GPX4-directed intervention.

• IP3R/Ca2+/STAT3 in Nanoplastic–Cadmium Toxicity

  2026-09-13

  A 2026 Toxicology study links polystyrene nanoplastic–cadmium co-exposure to intestinal apoptosis through the IP3R/Ca2+/STAT3 axis. Complementary C. elegans and Caco-2 experiments, including calcium chelation, provide functional evidence that intracellular Ca2+ dysregulation contributes to the toxic response.

• Wnt agonist 1: Applied Research Workflow

  2026-09-12

  Wnt agonist 1, also known as BML-284, provides a controllable small-molecule route to canonical Wnt signaling pathway activation in differentiation, developmental, and cancer models. This workflow connects TCF reporter measurements with the glutathione, GPX4, and platinum-resistance biology highlighted in a lung cancer brain-metastasis study.

• G007-LK: An Assay-First Tankyrase Inhibitor

  2026-09-11

  G007-LK is a selective tankyrase 1/2 inhibitor for dissecting Wnt, β-catenin, and Hippo pathway biology. This assay-first guide connects molecular mechanism with model selection, orthogonal readouts, and interpretation of colorectal and hepatocellular carcinoma data.

• 7ACC2 for Reliable Cancer Metabolism Assays

  2026-09-11

  This scenario-driven guide explains how 7ACC2, SKU B4868, can support reproducible studies of lactate transport, mitochondrial pyruvate handling, cell viability, and cancer metabolism. It separates product-backed evidence from workflow recommendations so researchers can interpret metabolic and cytotoxicity endpoints without overclaiming mechanism.

• Exendin-4 A3408: Reliable Beta-Cell Assays

  2026-09-10

  This scenario-driven guide explains how Exendin-4 (SKU A3408) can improve the design and interpretation of beta-cell, viability, proliferation, and cytotoxicity workflows. It connects dose selection, aqueous handling, cAMP biology, assay controls, and vendor evaluation to practical laboratory decisions.

• Monomethyl auristatin E in State-Aware ADC Studies

  2026-09-10

  Monomethyl auristatin E (MMAE) enables highly sensitive payload-response studies when free drug, antibody-drug conjugate delivery, and tumor cell state are evaluated separately. This workflow connects tubulin-directed cytotoxicity with the EBV-associated plasticity biology of nasopharyngeal carcinoma while clearly distinguishing established evidence from translational hypotheses.

• AR and ARv7 in TNBC: EPI-001 Evidence

  2026-09-09

  This 2025 study integrates patient immunohistochemistry, TCGA-BRCA analysis, and MDA-MB-231 experiments to examine AR and ARv7 in triple-negative breast cancer. Its findings associate ARv7, especially nuclear ARv7, with adverse outcomes and show that EPI-001 and enzalutamide modulate metastasis and epithelial–mesenchymal transition markers through pathways involving ROCK, NF-κB, and c-Myc.

• CFTRinh-172 Workflows for CFTR Transport Studies

  2026-09-09

  CFTRinh-172 enables rapid, reversible separation of CFTR channel activity from trafficking and signaling effects. This guide translates that distinction into epithelial transport workflows, surface-abundance controls, secretory diarrhea models, and practical troubleshooting strategies.

• CCCP: Mitochondrial Proton Gradient Uncoupler

  2026-09-08

  CCCP, also called carbonyl cyanide m-chlorophenyl hydrazine, dissipates the mitochondrial proton gradient and uncouples ATP production from respiratory electron flow. Its strongest research use is as a controlled bioenergetic perturbation, not as a clinical or diagnostic reagent.

• DeferoxamineB: Iron Chelation in Cancer Research

  2026-09-08

  Deferoxamine is an Fe(III)-chelating research compound used to test iron dependence, oxidative stress, and regulated cell death in biological models. DeferoxamineB supports ferroptosis-focused assay design, but results should not be interpreted as direct evidence of cuproptosis, apoptosis, or autophagy without pathway-specific controls.

• GSK621: A Practical AMPK Agonist Workflow

  2026-09-07

  GSK621 provides a direct way to interrogate AMPK-driven metabolic remodeling, mTORC1 suppression, autophagy, and apoptosis in AML and immunometabolic models. This workflow connects target engagement assays with practical optimization steps and the 25-hydroxycholesterol–AMPK pathway described in tumor-associated macrophages.

• Azithromycin Workflows for Infection Research

  2026-09-07

  Azithromycin supports practical workflows spanning bacterial infection research, resistance screening, analytical quality control, and investigational trypanosomosis studies. This guide connects its 50S-ribosome mechanism with solvent handling, impurity control, washout experiments, and assay-specific troubleshooting.

• Ibrexafungerp Activity at Vaginal pH

  2026-09-05

  The reference study tested ibrexafungerp, also known as MK 3118, against 187 vaginal Candida isolates under neutral and acidic conditions relevant to vulvovaginal candidiasis. Its central finding was that acidic pH did not materially reduce in vitro activity, including against fluconazole-resistant Candida, supporting pH-controlled susceptibility workflows while not substituting for clinical or in vivo efficacy studies.

8319 records 1/555 page Next 12345 下5页 Last page